Model group (n = 265) | Validation group (n = 300) | P value | |
---|---|---|---|
Death [n (%)] | 98 (37.0) | 161 (53.7) | < 0.001 |
Survival time (mean ± SD, month) | 20.6 ± 18.8 | 33.7 ± 29.8 | 0.008 |
Age (mean ± SD, year) | 64.4 ± 10.6 | 61.9 ± 11.4 | < 0.001 |
Male [(n) %] | 175 (66.0) | 199 (66.3) | 0.941 |
AJCC Stage (IV/III/II/I/NA) | 23/103/91/41/7 | 77/95/98/30/0 | < 0.001 |
AJCC PT (T4/T3/T2/T1/NA) | 66/121/62/16/0 | 21/91/188/0/0 | < 0.001 |
AJCC PN (N4/N3/N2/N1/N0/NA) | 4/49/55/67/88/2 | 0/51/80/131/38/0 | 0.011 |
AJCC PM (M2/M1/M0/NA) | 9/13/243/0 | 0/27/273/0 | 0.869 |
Targeted molecular therapy (yes/no/NA) | 78/79/108 | NA | |
Radiation treatment adjuvant (yes/no/NA) | 0/155/110 | NA | |
History other malignancy (yes/no/NA) | 6/259/0 | NA | |
Barretts esophagus (yes/no/NA) | 12/151/102 | NA | |
H pylori infection (yes/no/NA) | 15/117/133 | NA |